Vanguard Capital Management
ATNM icon

Vanguard Capital Management’s Actinium Pharmaceuticals ATNM Stock Holding History

Vanguard Capital Management’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.21M Sell
1,238,302
-17,214
-1% -$19.9K ﹤0.01% 3554
2026
Q1 		$1.25M Buy
+1,255,516
New +$1.49M ﹤0.01% 3499

Other funds holding ATNM

CFM
Compass Financial Management Tampa, Florida $829M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GWP
Gen-Wealth Partners Zeeland, Michigan $360M AUM 27.44% 1-Year Est. Return

Vanguard Capital Management's ATNM Position: Q2 2026 in Review

Vanguard Capital Management reduced its Actinium Pharmaceuticals (ATNM) stake by 1.4% in Q2 2026, selling an estimated $19.9K and leaving 1,238,302 shares worth $1.21M. The position accounts for ﹤0.01% of the portfolio, ranked #3554.

Vanguard Capital Management first reported a position in ATNM in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.25M in Q1 2026. 46 funds tracked by Wall St. Rank hold ATNM as of Q2 2026.

  • Vanguard Capital Management held 1,238,302 shares of Actinium Pharmaceuticals worth $1.21M as of Q2 2026.
  • Vanguard Capital Management sold 17,214 Actinium Pharmaceuticals shares in Q2 2026, an estimated $19.9K.
  • Actinium Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3554 holding.
  • Vanguard Capital Management first reported a position in Actinium Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Actinium Pharmaceuticals position peaked at $1.25M in Q1 2026.
  • 46 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.